Drug metyrapone shows promise for Cushing's patients who Can't have surgery
NCT ID NCT05255900
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the drug metyrapone in 20 people with mild Cushing's syndrome who were not candidates for surgery. Over 24 weeks, researchers measured changes in blood pressure, blood sugar, cholesterol, bone health, and mental health. The goal was to see if metyrapone could help control these problems caused by high cortisol levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- metyrapone
- What this could lead to
- If successful, metyrapone could become a treatment option for patients with mild Cushing's syndrome who cannot have surgery, helping control blood pressure and blood sugar.
- What could go wrong
- This is a small, completed study with only 20 participants, so results may not apply to everyone. Metyrapone can cause side effects like nausea or low blood pressure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERCORTISOLISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Istituto Auxologico Italiano
Milan, 20149, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New Needle-Free treatment could replace surgery for adrenal tumors
- Radiation-Free bone scan tested in kids
- Could a simple saliva test replace blood draws for cortisol screening?
- New drug aims to tame cortisol overload from adrenal tumors
- Hidden hormone problem may be worsening diabetes
- New PET tracer aims to reveal hidden Hormone-Making tumors